What do you know about ATMPs? Equip yourself for the future – learn the basics of Advanced Therapy Medicinal Products (ATMP). Join in and take the Swedish healthcare into the future!
A 15 minute introductory course produced within the activities of the Vinnova financed Advanced Therapy Medicinal Products (ATMP) Innovation Millieu towards Sweden being ”world leading in ATMP by 2030”. Pedagogic content and concrete examples to increase the basic knowledge level of all professionsals who in some way may come in contact with ATMPs.
The course is available in both Swedish and English!
More information about the course and registration, you can find on ATMP Sweden's website.
The Swedish Medical Products Agency is hosting a webinar about advanced therapies, ATMP. The webinar will be held in Swedish.
The Swedish Medical Products Agency (Läkemedelsverket) is hosting a webinar about advanced therapies, with the theme Advanced Therapy Medicinal Products, ATMP.
Last day for registration is May 28th.
The webinar will be held in Swedish.
Hans-Gustaf Ljunggren, Director, will participate in the digital event - Cell & Gene Therapy 2021, May 18-19. Hans-Gustaf will present one of the Competence Center’s projects - Autologous NK Cells as Consolidation Therapy in Multiple Myeloma.
The first ELRIG meeting on Advances in Cell and Gene Therapies will be held as a virtual event on the 18th and 19th of May 2021. The meeting will bring scientists from academia, pharma, biotech, and CRO’s together to engage with speakers at the cutting edge of developing and applying cell and gene therapies.
The three key focus areas of the meeting are:
For more information about the meeting, visit the meeting's official website.
The symposium is a joint mini symposium between the NextGenNK partners Karolinska Institutet and Sanofi.
Time for the symposium: April 27, 2021, 3pm-6pm CEST
In this symposium you will be given the opportunity to listen to world leading researchers, from the Karolinska Institutet, presenting frontlines of NK cell research and immunotherapy. In addition, Sanofi will present an overview of the company’s strong pipeline within NK cell therapeutics, followed by a panel discussion.
XNK Therapeutics AB (“XNK”) has entered into a joint Phase II clinical study to treat patients with multiple myeloma using XNK’s drug candidate in combination with Sanofi’s anti-CD38 antibody Sarclisa (isatuximab)
The investigator initiated Phase II study is made possible by four parties’ engagement in the trial. XNK will provide its novel autologous NK cell-based product for the study, set to take place at the Karolinska University Hospital in Stockholm, Sweden. XNK, Sanofi, and Karolinska University Hospital are all collaborative partners within NextGenNK, which is coordinated by Karolinska Institutet.
“Performing this Phase II study together with Karolinska Institutet is an important step for XNK in its ambition to combat multiple myeloma,” said Johan Liwing, CEO of XNK Therapeutics. “Combining our efforts together with the present partners highlights just how far XNK has progressed with its patented technology platform.”
The study, ISA-HC-NK (EudraCT: 2020-000994-26), compares XNK’s drug candidate combined with isatuximab against isatuximab as a consolidation treatment following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma.
Seminarierna arrangeras inom ramen för Vinnovas program Biologiska läkemedel.
Det finns stora möjligheter med användning av biologiska läkemedel i den svenska sjukvården. För att lyckas behövs starkare koppling mellan forskning, näringsliv och sjukvård, ett utvecklat internationellt samarbete och fokus på att utveckla ny individanpassad diagnostik och behandling.
Moderator Karin Aase, Vinnova
Under pauser och efter seminariet finns möjlighet att utforska digitala posters från pågående projekt inom programmet Biologiska läkemedel.